|Home | About | Journals | Submit | Contact Us | Français|
The pregnane x receptor (PXR) is a nuclear receptor transcription factor regulating drug-metabolizing enzymes and transporters that facilitate xenobiotic and endobiotic detoxification. Recent studies demonstrate that PXR is important in abrogating intestinal tissue damage. This study examines the role of PXR in lipopolysaccharide (LPS)/D-galactosamine (GalN)-induced acute liver injury using wild type and PXR-null mice. LPS/GalN-treated PXR-null mice had greater increases of alanine aminotransferase (ALT), hepatocyte apoptosis, necrosis, and hemorrhagic liver injury than wild type mice. LPS/GalN-mediated phosphorylation of JNK1/2 and ERK1/2 was differentially regulated in wild type and PXR-null mice. Importantly, LPS/GalN-induced hepatic Stat3 survival signaling was impaired and early activation of Jak2 was delayed in PXR-null mice. Expression levels of pro-survival proteins Bcl-xL and heme oxygenase-1 (HO-1), which are downstream of Stat3, were substantially lower in PXR-null than wild type mouse livers after LPS/GalN treatment. Autophagy is also involved in LPS/GalN-induced liver injury. Lack of PXR resulted in a significant reduction of LC3B-I, -II as well as Beclin-1 protein levels after LPS/GalN treatment. Taken together, PXR is a critical hepatoprotective factor. Increases of LPS/GalN-induced hepatocyte apoptosis and liver injury in PXR-null mice are due to deregulated MAP kinase activation as well as delayed Jak2/Stat3 activation, which lead to a compromise in defense mechanisms that involve Bcl-xL-, HO-1, and autophagy-mediated pathways.
The binding of TNFα to TNFR1 induces rapid activation of several intracellular signaling pathways that influence cell survival and death (1). Among them, nuclear factor κB (NF-κB) is the major transcription factor that regulates anti-apoptotic proteins and prevents cells from TNFα-induced apoptosis (1, 2). Deletion of p65RelA, a key player of NFκB signaling, causes severe hepatocyte apoptosis and embryonic lethality due to defective NFκB signaling and uncontrolled TNFα toxicity (3). The Stat3 transcription factor also plays an essential role in cell growth and apoptosis. Mice with specifically blocked hepatocyte Stat3 activation have increased apoptosis and liver injury induced by lipopolysaccharide (LPS), suggesting that Stat3-mediated survival signaling protects hepatocytes from TNFα-induced apoptosis (4). In addition, activation of Stat3 blocks toll like receptor-mediated inflammation (5). TNFα can induce mitogen-activated protein kinases (MAP kinases), including JNK1/2, ERK1/2, and p38, which transmit extracellular signals into their intracellular targets to regulate cell proliferation, differentiation, and apoptosis (1). Activation of MAP kinases has dual roles and presents both pro-apoptotic and anti-apoptotic functions in TNFα-mediated cell death events. JNK knockout mice are resistant to TNFα-induced liver injury indicating JNK mediates cell death signaling and promotes liver injury (6). In general, ERK signaling has been considered to mediate cell survival; however, increasing evidence demonstrates that ERK pathway also mediates apoptosis and tissue damage induced by different stimuli in different tissues (7–9). Depending on cell type or model of damage, inhibition of p38 can enhance (10) or prevent (11) TNFα-induced apoptosis, thus the role of p38 in TNFα-induced cell or tissue injury remains controversial.
Nuclear receptor pregnane x receptor (PXR) regulates a range of genes associated with clearance of endobiotics and xenobiotics. Recent research has revealed the important role of PXR in intestine injury and inflammatory processes (12–14). Crosstalk between PXR and NFκB has been reported (12). Using in vitro models, it has been implicated that activated human PXR (hPXR) suppresses NFκB and its target genes in primary human hepatocytes and intestinal LS180 cells (12). Activation of rodent PXR ameliorates dextran sulfate sodium-induced colitis through repression of NF-κB target genes (13). Notably, activated PXR also directly up-regulates anti-apoptotic proteins such as Bcl-xL and Bcl-2 in cultured hepatocytes (15) and colon cancer cells (16). Activation of PXR inhibits human hepatic stellate cell trans-differentiation in vitro (17) and in carbon tetrachloride-induced liver fibrosis mouse model (18). PXR also provides neuroprotection in a mouse model of Niemann-Pick C disease (19).
Despite emerging reports about the regulatory role of PXR in many physiological and pathological conditions, little is known about whether PXR regulates acute hepatic injury in vivo and whether survival or pro-apoptotic signaling pathways are affected due to lack of PXR. LPS/D-galactosamine (GalN) treatment of mice is a classic model of acute liver injury. GalN is a specific hepatotoxic transcriptional inhibitor that abolishes protection of NFκB and sensitizes liver towards subtoxic amounts of LPS (20) and TNFα is the predominant mediator that induces hepatocyte apoptosis and liver injury (21, 22). Our study examines the in vivo role of PXR in LPS/GalN-induced acute liver injury using wild type and PXR-null mice. We specifically determined the in vivo impact of PXR on LPS/GalN-induced activation of hepatic MAP kinases and Stat3 as well as the downstream survival and death pathways. Our results are the first to demonstrate that loss of PXR potentiates LPS/GalN-induced hepatocyte apoptosis and liver injury. The enhanced liver injury found in PXR-null mice is associated with delayed activation of hepatic Stat3, deregulated phosphorylaton of MAP kinases, and a compromise in anti-apoptotic signaling.
Antibodies specific for phospho-Akt (Thr308), pan-Akt; phospho-Stat3 (Tyr705), phospho-Stat3 (Ser727), Stat3; phospho-SAPK/JNK (Thr183/Tyr185), SAPK/JNK; phospho-p38 MAP kinase (Thr180/Tyr182), p38 MAP kinase; phospho-ERK1/2 MAP kinase (Thr202/Tyr204), ERK1/2 MAP kinase; phospho-Jak1 (Tyr1022/1023); phospho-Tyk2 (Tyr1054/1055); phospho-Jak2 (Tyr1007/1008), Jak2; cleaved caspase-3 (Asp175), Bcl-xL and Bax were purchased from Cell Signaling Technology. Antibody specific for phosphor-p65 (Ser311), HO-1 were purchased from Santa Cruz Biotechnology Inc. Antibody for glyceraldehyde 3-phosphate dehydrogenase (gapdh) was purchased from Abcam. LPS from Escherichia coli 0127: B8 and GalN were purchased from Sigma-Aldrich.
Wild type and PXR-null mice with a mixed background of C57/BL/6 and SVJ129 were kindly provided by Dr. Wen Xie at University of Pittsburgh and the generation of PXR-null mice were described previously (23, 24). All procedures were conducted in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and were approved by the Kansas University Medical Center Institutional Animal Care and Use Committee. Male mice (9–11 weeks, n=5 for each treatment group or time point) were administered with one intra-peritoneal (i.p.) dose of 100 μg/kg of LPS and 700 mg/kg of GalN dissolved in sterile 0.9 % saline, control mice were injected with sterile 0.9 % saline. Livers were removed at 0, 1, and 5 h post LPS/GalN injection. Stock LPS was dissolved in sterilized saline at 1 mg/ml and sonicated for 5 min, aliquot and stored at −80°C. LPS and GalN were freshly prepared before usage. ALT levels were monitored using the Liquid ALT Reagent kit (Pointe Scientific Inc.).
Liver tissues were fixed with 10% buffered formalin/PBS, embedded in paraffin. Liver sections (5 μm) were stained with hematoxylin and eosin (H&E) following standard protocol. TUNEL assay was performed using the In Situ Cell Death Detection kit (Roche Molecular Biochemicals).
Liver proteins (40–100 μg) were separated on sodium dodecyl sulfate-polyacrylamide gel (10–15 %) and then electro-transferred to PVDF membranes. Membranes were incubated with primary antibody overnight at 4°C, followed by incubation with secondary antibody and detected by enhanced chemical luminescence kit. Membranes were re-probed with anti-Gapdh antibody to monitor equal loading of protein. Representative blots are shown in the figures. Densitometry analysis was performed to quantify protein bands.
The results (ALT levels) were analyzed using Student's t test. All data expressed as mean ± SD. P < 0.05 was considered significant.
Five h after LPS/GalN injection, PXR-null mice had higher serum ALT (about 1,100 IU/L) than that of wild type mice (about 150 IU/L) (Figure 1A). LPS/GalN treatment caused apoptotic, focal necrotic, and hemorrhagic injury in the livers of PXR-null mice; in contrast, apoptosis and necrosis was much less in the livers of LPS/GalN-treated wild type mice. Importantly, no massive hemorrhage present in the livers of wild type mice (Figure 1B). Thus, in the absence of PXR, LPS/GalN-induced liver injury is potentiated. Sporadic apoptotic hepatocytes and neutrophil infiltrations occasionally present in the liver sections of saline-treated PXR-null mice (Figure 1B, arrow and triangle), although livers of saline-treated wild type mice had normal morphology (Figure 1B). These findings suggest PXR provides hepato-protective effects.
Five h post LPS/GalN injection, phosphorylation of hepatic JNK1/2 (Thr183/Tyr185) (p-JNK1/2) was much higher in PXR-null than wild type mice (Figure 2). One h post LPS/GalN injections, levels of p-ERK1/2 (Thr202/Tyr204) were substantially reduced in both genotypes; however, trace levels of hepatic p-ERK1/2 were still detected in wild type mice, but not in PXR-null mice (Figure 2). Five h after treatment, levels of p-ERK1/2 were higher in PXR-null than wild type mice. PXR-null mice had increased basal levels of p-p38 (Thr180/Tyr182) (Figure 2). Similar to the expression pattern of ERK1/2, LPS/GalN treatment transiently reduced p-p38 within 1 h. At 5 h, levels of p-p38 were slightly higher in PXR-null than wild type mice. Thus, rapid and substantial deactivation of MAP kinases at early time point (1 h) and elevated activation of MAP kinases at late time point (5 h) were associated with increased and accelerated liver injury in PXR-null mice.
One h post LPS/GalN injection, p-Stat3 (Tyr705) present only in wild type mice (Figure 3A). In contrast, p-Stat3 (Tyr705) was detected in PXR-null mice 5 h post injection (Figure 3A). In addition, LPS/GalN induced similar levels of p-Stat3 at Ser727 in wild type and PXR-null mice (Figure 3A). Since Stat3 mediates survival signaling in LPS/GalN-induced liver injury, the impaired activation of hepatic Stat3 at Tyr705 might account for the increased liver injury in PXR-null mice.
Activation of Akt provides protective effects against TNFα-mediated apoptosis in endothelial cells (25), renal cells (26), and liver injury model (27). As shown in Figure 3B, PXR-null mice had slightly increased basal p-Akt (Thr308), which was similar to the pattern of p38. LPS/GalN reduced the levels of p-Akt in wild type and PXR-null mice and the reduction seems more pronounced in PXR-null than wild type mice (Figure 3B).
Stat3 is selectively phosphorylated by the upstream Janus protein kinase (Jak) family, which includes Jak1-3 and Tyk2. Jak1, Jak2, and Tyk2 are widely expressed, whereas Jak3 is primarily found in lymphoid and myeloid cells (28). Since p-Stat3 (Tyr705) was delayed in LPS/GalN-treated PXR-null mice, we examined whether lack of PXR affects activation of kinases upstream of Stat3. One h post LPS/GalN injection, increased hepatic p-Jak2 (Tyr1007/1008) occurred only in wild type, but not in PXR-null mice; at 5 h, wild type and PXR-null mice had similar levels of p-Jak2 (Figure 4). LPS/GalN did not induce hepatic p-Jak1 (Tyr1022/1023) until 5 h post LPS/GalN injection in both genotypes of mice, and the induction was weak. Therefore, Jak2, but not Jak1, is mostly associated with LSP/GalN-mediated Stat3 activation. In addition, LPS/GalN did not change the level of hepatic p-Tyk2 (Tyr1054/1055) in wild type and PXR-null mice at 1 h. At 5 h, the levels of p-Tyk2 were slightly reduced in PXR-null mice. Thus, loss of PXR primarily affects LPS/GalN-induced p-Jak2 at 1 h (Figure 4). The data indicate that the impaired activation of Jak2 accounts for the delayed activation of Stat3 in PXR-null mice.
We performed western blot analysis using antibody specific to phosphorylated p65 (p-p65). The basal p-p65 increased due to lack of PXR (Figure 5). LPS/GalN further increased activation of p-p65, and the levels of p-p65 were much higher in PXR-null than wild type mice (Figure 5). The highest levels of p-p65 were observed in the livers of PXR-null mice at 5 h, which was correlated with activation of Stat3 at the same time point in PXR-null mice. Our results indicate that in the absence of PXR, activation of p65 is enhanced, which may cause deregulated TNFα and/or IL-6 release as well as Stat3 activation.
LPS/GalN-induced hepatocyte apoptosis was examined by TUNEL staining. Five h post LPS/GalN injection; PXR-null mice had three times more TUNEL positive hepatocytes than wild type mice did (Figure 6A–B). One h post LPS/GalN injection, cleaved caspase-3 was not detected in the livers of wild type and PXR-null mice (data not shown). At 5 h, PXR-null mouse livers had a greater increase of cleaved caspase-3 in comparison with wild type mice (Figure 6C). Thus, when PXR is absent, hepatocytes are vulnerable to LPS/GalN-induced apoptotic injury and the commencement of hepatocyte apoptosis is accelerated.
The relative levels of pro- and anti-apoptotic proteins are the key determinants and regulators of cell survival and death (29, 30). PXR regulates anti-apoptotic proteins Bcl-xL and Bcl-2 in primary hepatocytes (15) and colon cancer cells (16). Since Bcl-xL, but not Bcl-2, has been implicated to have a protective role in LPS/GalN-induced acute hepatic failure model (31, 32), we hypothesized that a lack of PXR might affect downstream anti-apoptotic proteins in LPS/GalN-induced liver injury. The basal levels of Bcl-xL were slightly decreased due to lack of PXR. LPS/GalN transiently and weakly increased Bcl-xL levels in both genotypes of mice. Overall, the levels of Bcl-xL were lower in PXR-null than wild type mouse livers (Figure 7A). HO-1 is a stress-responsive enzyme that has been implicated as a protective protein through anti-apoptotic, anti-inflammatory, and anti-oxidant actions (33, 34). HO-1 is directly regulated by Stat3 and can protect mice from LPS/GalN-induced apoptotic liver injury (35). Western blot analysis revealed that wild type mouse livers had rapid transient induction of HO-1 protein at 1 h, which did not occur in PXR-null (Figure 7A). HO-1 proteins decreased in both genotypes at the time (5 h) when stat3 was highly activated. The results indicate that delayed early activation of Stat3 may not able to result in sufficient transcription of HO-1. Impaired transcription machinery due to severe liver injury at 5 h may also partly account for the reduction of HO-1. In addition, the levels of Bax were slightly and transiently induced only in LPS/GalN-treated wild type mice at 1 h (Figure 7A). Thus, in the absence of PXR, the hepatic anti-apoptotic pathways are compromised in response to LPS/GalN.
Autophagy promotes survival by removing unwanted cellular substances and by providing nutrients under starvation conditions (36). It could, however, also contribute to cell death if the process is deregulated (36). The role of autophagy in LPS/GalN-induced liver injury has not been studied. We found that LPS/GalN induced LC3B (Figure 7B), a marker of autophagy (37), within 1 h in both genotypes. LC3B-II, which is converted from LC3B-I by lipidation, is located on the autophagic vacuoles (37). Five h after treatment, LPS/GalN-induced expression of LC3B-I and -II was sustained in the livers of wild type mice. In contrast, LC3B-I and -II proteins of PXR-null mice rapidly dropped to levels lower than basal levels. The levels of Beclin 1, which is a necessary participant in autophagic vacuoles formation and also takes part in trafficking of lysosomal proteins (38, 39), were reduced by LPS/GalN treatment in both genotypes (Figure 6B). However, the reduction was transient in wild type but sustained in PXR-null mouse livers. Taken together, our results indicate that autophagy does play a role in LPS/GalN-induced liver injury and that autophagy is likely a defensive mechanism to protect liver from injury. The hepatoprotective effects of autophagy are compromised due to lack of PXR.
The current study focuses on the in vivo role of PXR in LPS/GalN-induced hepatocyte apoptosis and liver injury. The data indicate that in response to LPS/GalN, PXR-null mice had increased hepatocyte apoptosis and augmented liver injury, which suggests the protective role of PXR in LPS/GalN-induced acute liver injury. Our findings suggest that 1) PXR is essential for Jak2/Stat3-mediated survival signals; 2) PXR is implicated in MAP kinase pathways and regulates cell survival; and 3) PXR confers anti-apoptotic effects through Bcl-xL, HO-1, and autophagy.
LPS/GalN treatment caused increased apoptotic, necrotic, and hemorrhagic liver injury in PXR-null mice in comparison with wild type mice, suggesting PXR is critical for cell survival. Once bound to TNFα, TNFR1 recruits adaptor proteins leading to activation of MAP kinases in the liver (1). Previous studies have demonstrated that JNK inhibitor SP600125 prevents mice from LPS-induced liver injury (40) and JNK knockout mice are resistant to TNFα-induced liver damage (6, 41). It is believed the pro-apoptotic role of JNK1 occurs through activation of E3 ubiquitin ligase Itch and sequential degradation of anti-apoptotic protein c-FlipS/L (41), whereas JNK2 directly activates caspase-8 and promotes apoptosis (6). Together with other results, our findings of increased hepatic p-JNK1/2 in PXR-null mice suggest that abrogation of PXR facilitates LPS/GalN-induced JNK activation which is associated with increased hepatocyte apoptosis. P38 inhibitor SB203580 attenuates LPS-induced liver injury in mice with increased CYP2E1 activity through anti-oxidative stress mechanisms (40). Controversially, hepatocyte p38α-deficient mice have exacerbated JNK activation and aggravated LPS-induced hepatic apoptosis and liver injury (11). Although the effect is mild, LPS/GalN treatment resulted in a transient reduction of hepatic p-p38. However, reactivation of hepatic p38 was more apparent in PXR-null than wild type mouse 5 h post LPS/GalN injection, which coincided with the activation of JNK1/2, ERK1/2, and apoptosis. Activation of ERK1/2 has been proposed to promote cell proliferation and cell cycle of several cell types including cancer cells. On the contrary, accumulating reports demonstrate that activation of ERK1/2 is associated with tissue injury including lung (42–44), liver (45, 46), and kidney (47). In addition, MEK1 inhibitor PD98059 attenuates liver injury after trauma-hemorrhage (44), indicating that ERK1/2 promotes cell death. Our findings, which show a rapid deactivation of ERK1/2 and lack of p-ERK1/2 in PXR-null livers within 1 h LPS/GalN injection, indicate a pro-survival role of ERK1/2 at early time point. Reactivation of ERK1/2 and higher levels of p-ERK1/2 in PXR-null than in wild type mice, which coincided with increased p-JNK1/2 as well as cell death and injury at 5 h, suggests a pro-death role of p-ERK1/2 at later time point. Taken together, deregulated phosphorylation of hepatic JNK1/2 and ERK1/2 is found in PXR-null mice. Thus, MAP kinase pathways are implicated in liver injury found in PXR-null mice.
Stat3 plays an important role in cell survival and carcinogenesis through regulation of proliferation and apoptosis (48). Liver-specific inactivation of Stat3 leads to increased hepatocyte apoptosis in mice (4). Stat3 over-expression in rat hepatocytes provides protection against hypoxia/re-oxygenation-induced injury (49). Promotion of Stat3 confers resistance to apoptosis and accelerated proliferation, resulting in enhanced hepatitis-induced hepatocarcinogenesis (50). Phosphorylation of Stat3 at Tyr 705 is mediated by Jak family, allowing Stat3 to form dimer and regulate transcription. Phosphorylation of Stat3 at Ser727 can be regulated by many serine kinases besides Jaks. ERK1/2, mTOR, Vav, Rac-1, and SEK-1/MKK-4 can all phosphorylate Stat3 at Ser727 depending on extracellular stimulus and cell type. De-phosphorylation of Stat3 terminates its activity. In cytoplasm, tyrosine phosphoatases, such as SH-2-containing phosphatase 1 (SHP1), SHP2, and protein-tyrosine phosphatase 1B can prevent Stat3 activation. Suppressor of cytokine signaling negatively regulates Stat3 activation. In nucleus, protein inhibitor of activated Stat family blocks Stat-DNA binding. In addition, Stat3 can be de-phosphorylated by nuclear tyrosine phosphatases TC45 that allows it return to cytoplasm. Recently, it has been uncovered that KAP-1a, a universal co-repressor protein for Kruppel-associated box zinc-finger protein, accelerates de-phosphorylation of Stat3 (51). Thus, phosphorylation of Stat 3 is a dynamic process and can be complicated. Our data demonstrate that LPS/GalN-induced hepatic Stat3 phosporylation at Tyr705 is delayed in PXR-null mice, suggesting that early survival signaling through Stat3 is compromised in the absence of PXR. Among the three upstream kinases that phosphorylate Stat3, only Jak2 (Tyr1007/1008) early activation is markedly blocked due to PXR deficiency. Phosphorylation of Stat3 at Ser727 was comparable between wild type and PXR-null mice, thus, PXR does not affect activation of Stat3 at Ser727. Together, our results demonstrate a novel function of PXR, that is, PXR positively and preferentially regulates LPS/GalN-induced phosphorylation of Jak2, which is associated with the protective action of PXR in vivo. Additional study needs to be done to determine how PXR regulates Jak2 activation.
The anti-apoptotic effects of PXR have been observed in primary human or rat hepatocytes through up-regulation of Bcl-xL and Bcl-2. Down regulation of PXR contributes to cell growth inhibition and apoptosis in endometrial cancer cells. The crucial role of Bcl-xL in antagonizing Bid-mediated hepatocyte apoptosis is evidenced by the fact that mice with hepatocyte specific-Bcl-xL deficiency develop spontaneous and continuous apoptosis (52). Bcl-xL, but not Bcl-2, has been implicated in the protection of LPS/GalN-induced acute hepatic failure model (31, 32, 53). In line with the above reports, we found that protein levels of Bcl-xL were reduced in the livers of untreated as well as LPS/GalN-treated PXR-null mice. Bcl-xL is also one of the Stat3 target genes (54), correspondingly, we observed that the Bcl-xL levels were higher in wild type than PXR-null mice 1 h after the treatment. Thus, it is likely that impaired activation of Stat3 in PXR-null mice may affect expression and function of Bcl-xL. HO-1 system has been shown to protect tissue from injury in liver (35), lung (55, 56), and intestine (57, 58), after LPS/GalN (59) or LPS treatment (35), ischemia-reperfusion (60), and transplantation (57, 58) through anti-apoptosis, anti-oxidant, and anti-inflammation actions. More recently, HO-1 and Stat3 are implicated in the protection against hyperoxia-induced lung injury (61). The underlying mechanisms include Stat3-mediated activation of HO-1 and consequential increases of its product, carbon monoxide, which in turn increases Stat3 activation. Induction of HO-1 can activate its downstream survival targets such as pAkt, Bcl-xL, and Bcl-2 (61). We found that LPS/GalN-induced early increase of HO-1 was markedly reduced in the livers of PXR-null mice, which is well correlated with the decreased pro-survival molecules Bcl-xL and pAkt in PXR-null mice. In addition, down regulation of Bax protects mice from GalN/TNFα-induced liver damage (62). The fact that LPS/GalN modestly induced Bax in wild type mice, but not in PXR-null mice, indicates that PXR might not have a significant role in regulating Bax-mediated pro-apoptosis pathway. Our results point out that PXR positively regulates anti-apoptotic events mainly through Stat3, Bcl-xL, and HO-1. Stat3 modulates multiple downstream pro-survival pathways, of which Bcl-xL and HO-1 are only two; therefore, we could not exclude the possibility that there are additional pro-survival molecules regulated by Stat3 which confer protective effects.
Bcl-xL (54) and HO-1 (61) are critical survival genes directly regulated by Stat3. Bcl-xL is also regulated by PXR (15) and we consistently observed reduced basal levels of Bcl-xL protein in PXR-null mice. We also found LPS/GalN-induced HO-1 is greatly reduced due to lack of PXR. Our data indicate a presence of crosstalk between these two important transcription factors Stat3 and PXR and that they may or may not target overlapping downstream molecules that eventually confer significant protection against LPS/GalN-induced liver injury. As indicated in our data, sporadic hepatocyte apoptosis and neutrophil infiltration occurred in the livers of PXR-null mice. Neither elevated ALT nor cleaved caspase-3 was detected accordingly, but, slightly elevated basal levels of p-Stat3 (Tyr705), p-p38, and p-Akt as well as decreased basal levels of Bcl-xL were found in livers of PXR-null mice. Therefore, PXR is important in maintaining hepatocyte homeostasis. In the absence of PXR, the balance between pro-survival and pro-apoptosis is shifted. Our novel findings delineate a previously unacknowledged interdependence between PXR and Stat3 in vivo and help us to better understand the potential usage of PXR as a therapeutic target for acute liver injury.
We thank Dr. James P. Luyendyk for critical discussion, Mrs. Lin He for technical support, and Ms. Barbara Brede for editing this manuscript.
This work was supported by NIH grants CA53596, AA14147, and COBRE Molecular Biology Core, P20 RR021940.
CONFLICT OF INTEREST The authors declare no conflict of interest.